Price T Rowe Associates Inc. MD Lowers Position in Gossamer Bio, Inc. (NASDAQ:GOSS)

Price T Rowe Associates Inc. MD trimmed its position in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 99.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,777 shares of the company's stock after selling 6,369,269 shares during the period. Price T Rowe Associates Inc. MD's holdings in Gossamer Bio were worth $59,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Smith Moore & CO. grew its position in shares of Gossamer Bio by 32.7% during the 4th quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock valued at $271,000 after acquiring an additional 74,000 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Gossamer Bio by 1.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after buying an additional 13,902 shares during the period. Geode Capital Management LLC raised its position in shares of Gossamer Bio by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock valued at $2,037,000 after buying an additional 38,084 shares during the period. Monaco Asset Management SAM raised its position in shares of Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after buying an additional 1,520,721 shares during the period. Finally, Silverarc Capital Management LLC raised its position in shares of Gossamer Bio by 9.3% during the 4th quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock valued at $5,583,000 after buying an additional 526,495 shares during the period. 81.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on GOSS shares. Wedbush reaffirmed an "outperform" rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Friday, May 16th. The Goldman Sachs Group lifted their target price on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a report on Friday, May 16th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a report on Tuesday, March 18th.

Gossamer Bio Trading Up 3.4%

Gossamer Bio stock traded up $0.04 during trading on Friday, hitting $1.20. The company had a trading volume of 1,930,685 shares, compared to its average volume of 1,550,322. Gossamer Bio, Inc. has a 1-year low of $0.50 and a 1-year high of $1.55. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The company's 50 day simple moving average is $1.02 and its 200-day simple moving average is $1.00. The stock has a market cap of $272.76 million, a price-to-earnings ratio of -3.75 and a beta of 1.82.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $9.89 million during the quarter, compared to analyst estimates of $3.95 million. As a group, analysts expect that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.